The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Takeda (Gold).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
IASLC TTLC 2022 | The future of anti-PD-1 therapies in the NSCLC treatment landscape
Nathan Pennell, MD, PhD, Cleveland Clinic, Cleveland, OH, comments on advances in the use of PD-1 inhibitor in advanced non-small cell lung cancer (NSCLC). Whilst pembrolizumab plus chemotherapy has been successfully used in the clinic following data from the KEYNOTE-189 (NCT02578680) and KEYNOTE-407 (NCT02775435) trials, studies assessing anti-PD-1 with anti-CTLA-4 antibodies have failed to yield superior outcomes. Prof. Pennell additionally highlights the unreliability of trials that exclusively use chemotherapy as the standard of care. This interview took place at the 2022 Targeted Therapies of Lung Cancer Meeting (TTLC 2022).
